🔥🐔 BizChicken 🐔🔥

Companies Similar to Neurogene Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Precigen, Inc.

Precigen, Inc. logo
Market Cap: Low
Employees: Low

gene and cellular therapies

Precigen, Inc. is focused on discovering and developing advanced gene and cellular therapies, disease-modifying therapeutics, and genetic engineering technologies for regenerative medicine and other applications.

Tags: biotechnology, cellular therapy, gene therapy, genetic engineering, regenerative medicine

Symbol: PGEN

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Helen Sabzevari MPH, Ph.D.

Sector: Healthcare

Employees: 202

Address: 20374 Seneca Meadows Parkway, Germantown, MD 20876

Phone: 301 556 9900

Last updated: 2024-12-31

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. logo
Market Cap: Highest
Employees: Medium

INGREZZA

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for various conditions, focusing on innovative solutions for unmet medical needs.

Tags: Parkinson's disease, endocrine disorders, endometriosis, neurology, pharmaceuticals, psychiatric disorders, tardive dyskinesia, uterine fibroids

Symbol: NBIX

Recent Price: $137.06

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Kyle W. Gano Ph.D.

Sector: Healthcare

Employees: 1700

Address: 12780 El Camino Real, San Diego, CA 92130

Phone: 858 617 7600

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. logo
Market Cap: Medium
Employees: Lowest

TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101

Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.

Tags: CNS, biotechnology, gene therapy, healthcare, monogenic diseases

Symbol: TSHA

Recent Price: $1.73

Industry: Biotechnology

CEO: Mr. Sean P. Nolan

Sector: Healthcare

Employees: 52

Address: 3000 Pegasus Park Drive, Dallas, TX 75247

Phone: 214 612 0000

Last updated: 2024-12-31

Alzamend Neuro, Inc.

Alzamend Neuro, Inc. logo
Market Cap: Lowest
Employees: Lowest

AL001 and AL002

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing products for neurodegenerative and psychiatric disorders. Their pipeline includes AL001 for Alzheimer's and psychiatric disorders, and AL002 for Alzheimer's disease using a novel vaccine approach.

Tags: Alzheimer's, biopharmaceutical, clinical trials, mental health, neurodegenerative disorders, psychiatric disorders

Symbol: ALZN

Recent Price: $1.20

Industry: Biotechnology

CEO: Mr. Stephan Jackman

Sector: Healthcare

Employees: 4

Address: 3500 Lenox Road NE, Atlanta, GA 30326

Phone: 844 722 6333

Last updated: 2024-12-31

Generation Bio Co.

Generation Bio Co. logo
Market Cap: Low
Employees: Low

genetic medicines

Generation Bio Co. is a genetic medicines company developing therapies for rare and prevalent diseases, with a focus on the liver, retina, skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and is headquartered in Cambridge, Massachusetts.

Tags: CNS, genetic medicines, liver, oncology, prevalent diseases, rare diseases, retina, skeletal muscle

Symbol: GBIO

Recent Price: $1.06

Industry: Biotechnology

CEO: Dr. Cameron Geoffrey McDonough M.D.

Sector: Healthcare

Employees: 174

Address: 301 Binney Street, Cambridge, MA 02142

Phone: 617 655 7500

Last updated: 2024-12-31

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Low

LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004

Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.

Tags: APOE4, Batten disease, acquired diseases, cardiomyopathy, gene therapy, genetic medicine, hereditary diseases

Symbol: LXEO

Recent Price: $6.54

Industry: Biotechnology

CEO: Mr. R. Nolan Townsend

Sector: Healthcare

Employees: 69

Address: 345 Park Avenue South, New York, null 10010

Phone: 212-547-9879

Last updated: 2024-12-31

NeoGenomics, Inc.

NeoGenomics, Inc. logo
Market Cap: High
Employees: High

Cancer-focused testing services

Neo Genomics, Inc. operates a network of cancer-focused testing laboratories offering various services such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, digital imaging, and molecular testing.

Tags: cancer testing, cytogenetics, flow cytometry, laboratories, molecular testing, oncology

Symbol: NEO

Recent Price: $16.92

Industry: Medical - Diagnostics & Research

CEO: Mr. Christopher Michael Smith BSc

Sector: Healthcare

Employees: 2100

Address: 9490 NeoGenomics Way, Fort Myers, FL 33912

Phone: 239 768 0600

Leadership

  • Chris Smith, Chief Executive Officer
  • Jeff Sherman, Chief Financial Officer
  • Warren Stone, Chief Commercial Officer
  • Melody Harris, Chief Operations Officer & President, Informatics
  • Ali Olivo, Executive Vice President, General Counsel & Business Development
  • Hutan Hashemi, JD, Chief Compliance Officer
  • Nathan Montgomery, MD, PhD, Vice President, Medical Services
  • Gary Passman, Chief Culture Officer
  • Kareem Saad, Head of Strategy and Transformation
  • Lynn A. Tetrault, Chair of the Board
  • Bruce K. Crowther, Board Member
  • Elizabeth Floegel, Board Member
  • Neil Gunn, Board Member
  • Alison L. Hannah, MD, Board Member
  • Stephen Kanovsky, Board Member
  • Michael A. Kelly, Board Member
  • David Perez, Board Member
  • Tony Zook, Board Member
  • Derek Lyle, MD, Chief Medical Officer
  • Vladislav Chizhevsky, MD SSBBP, Medical Director, Aliso Viejo, California
  • J. Christopher Mixon, MD, Medical Director, Nashville, Tennessee
  • Anahit Nowrouzi, MD, Medical Director, Fort Myers, Florida
  • Tricia Peters, MD, Medical Director, Houston, Texas Molecular Pathologist, Pharma Services
  • Yin Xu, MD PhD FCAP, Medical Director, Carlsbad and Atlanta; Global Medical Director, Pharma Services
  • Renuka Agrawal, MD, Senior Hematopathologist
  • Todd S. Barry, MD PhD, Senior Hematopathologist
  • Bora Baysal, MD, PhD, Senior Hematopathologist
  • Saskia Boisot, MD, Senior Hematopathologist
  • Wayne W. Chen, MD PhD, Director of Hematopathology Services
  • Rachel Flamholz, MD, Senior Hematopathologist
  • Michael Hayes, MD, Senior Hematopathologist / Surgical Pathologist
  • Anselm Hii, MD, Director of Hematopathology Services
  • Thanh Ho, MD, Senior Hematopathologist
  • Kim Janatpour, MD MA, Senior Hematopathologist
  • Shiping Jiang, MD PhD, Senior Hematopathologist and Surgical Pathologist
  • Sameer S. Khatri, MD, Hematopathologist
  • Madeleine Kraus, MD, Senior Hematopathologist
  • Brian Kwok, MD FCAP, Corporate Director of Hematopathology
  • Keming Lin, MD MS FCAP, Senior Hematopathologist
  • Robert Lin, MD, Senior Hematopathologist
  • Russell L. Maiese, M.D., Senior Hematopathologist
  • Mojdeh Naghashpour, MD PhD, Senior Hematopathologist
  • Viera Nelson, MD, Senior Hematopathologist
  • Dennis P. O’Malley, MD, Senior Hematopathologist
  • Anthony Padula, MD, Senior Hematopathologist
  • Munir Shahjahan, MD MPH, Senior Hematopathologist
  • Jesalyn J. Taylor, MD, Senior Hematopathologist
  • Jian-Feng Wang, MD PhD, Senior Hematopathologist
  • Zhao Wu, MD PhD FCAP, Senior Hematopathologist
  • Aine Yung, MD FCAP, Senior Hematopathologist
  • Sadiq Zaman, MD, Senior Hematopathologist
  • Guohua Zhao, MD PhD, Senior Hematopathologist
  • Mitual Amin, MD, Senior Surgical Pathologist
  • Jerry Chu, MD PhD, Senior Surgical Pathologist
  • Ted Farzaneh, MD, Senior Surgical Pathologist
  • Thomas K. Lee, MD PhD, Director of Surgical Pathology Services
  • Takako Mitsuhashi, MD PhD, Senior Dermatopathologist and Surgical Pathologist
  • Robert Schwartz, MD, Senior Surgical Pathologist
  • Yae K (Kay) Suh, MD, Senior Surgical Pathologist
  • Matthew Geller, DO, Molecular Pathologist
  • Hao Ho, MD, Molecular Pathologist
  • Jennifer Hummel, MD, Senior Molecular Pathologist
  • Armen Kaysan, MD, Molecular Pathologist
  • Kalpana S. Reddy, MD, Hematopathologist and Molecular Pathologist
  • Saed Sadeghi, MD, Molecular Pathologist
  • Ying Wang, MD PhD, Molecular Pathologist
  • Shehla Arain, MD, Senior Surgical Pathologist, Pharma Services
  • Chunghun George Chang, md, Surgical and Hemepath Pathologist, Pharma Services
  • Indu Gupta, MD, Surgical Pathologist, Pharma Services
  • Valerie Harris-Morris, MD, Hemepath Pathologist, Pharma Services
  • Albert Ho, Director of Pharma Pathology Services
  • Henry Tsai, MD PhD, Surgical Pathologist, Pharma Services
  • Sujata Chakraborty, PhD FACMGG, Director, Cytogenetics and Molecular Genetics
  • Li Cheng, PhD FACMG, Associate Director of Cytogenetics
  • Liang Dong, MD PhD, Director of Cytogenetic Services
  • Mohamed M. Elnaggar, MD MS FACMG, Director of Cytogenetic Services
  • Michele Hibbard/Kempik, PhD FACMG, Director of Genetics
  • Fernando J. López-Díaz, PhD, Director of Clinical Science, Research and Development
  • John R. McGill, PhD FACMGG, Medical Director of Cytogenetics and Technical Director of FISH
  • Mike Nahorski, PhD, Director, Clinical and Scientific Alliances
  • Farzad Nooraie, MD, Director of Cytogenetic Services
  • Róisín Puentes, PharmD, PhD, Medical Science Liaison, Medical Affairs
  • Siby Sebastian, Ph.D, FACMGG, DABCC, Lab Director, Research Triangle Park (RTP), North Carolina
  • Guoxian Sun, MD DABMG FACMG, Director of Cytogenetic Services
  • Jadwiga Szymanska, PhD FACMG, Director of Cytogenetics
  • Maya Thangavelu, PhD, Medical Director of Cytogenetics and Technical Director of FISH
  • Qinqin Zha, PhD, Principal Scientist, Associate Director, Scientific Affairs
  • John N. Allan, MD, Scientific Advisory Board Member
  • Rafael Bejar, MD, PhD, Scientific Advisory Board Member
  • James R. Berenson, MD, Scientific Advisory Board Member
  • Riccardo Dalla-Favera, PhD, Scientific Advisory Board Member
  • James Downing, MD, Scientific Advisory Board Member
  • Bernard A Fox, PhD, Scientific Advisory Board Member
  • Gregory Hess, MD, Scientific Advisory Board Member
  • Hatim Husain, MD, Scientific Advisory Board Member
  • Tibor Kovacsovics, MD, Scientific Advisory Board Member
  • Razelle Kurzrock, MD, Scientific Advisory Board Member
  • Gail J. Roboz, MD, Scientific Advisory Board Member
  • Steven T. Rosen, MD, FACP, FASCO, FAIMBE, Scientific Advisory Board Member
  • Mark A. Rubin, MD, Scientific Advisory Board Member

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

PepGen Inc.

PepGen Inc. logo
Market Cap: Low
Employees: Low

PGN-EDO51

Pep Gen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for neuromuscular and neurologic diseases. Its lead product, PGN-EDO51, is in Phase I trials for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, biotechnology, clinical trials, neuromuscular diseases, oligonucleotide therapeutics

Symbol: PEPG

Recent Price: $3.83

Industry: Biotechnology

CEO: Dr. James G. McArthur Ph.D.

Sector: Healthcare

Employees: 72

Address: 245 Main Street, Cambridge, MA 02142

Phone: 781-797-0979

Last updated: 2024-12-31

Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

PT00114

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, aims to regulate stress response and restore healthy brain function.

Tags: biopharmaceutical, brain health, mood disorders, neuropsychiatric disorders, stress response, therapeutics

Symbol: PTIX

Recent Price: $0.54

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 1

Address: 149 Fifth Avenue, New York, NY 10010

Phone: 212 994 8200

Last updated: 2024-12-31

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Gene Therapies

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.

Tags: Biotechnology, Clinical Stage, Gene Therapy, Healthcare, Rare Diseases

Symbol: RCKT

Recent Price: $12.03

Industry: Biotechnology

CEO: Dr. Gaurav D. Shah M.D.

Sector: Healthcare

Employees: 268

Address: 9 Cedarbrook Drive, Cranbury, NJ 08512

Phone: 609 659 8001

Last updated: 2024-12-31

Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Pro Neura

Titan Pharmaceuticals, Inc. is a pharmaceutical company developing therapeutics for chronic diseases utilizing the Pro Neura drug delivery platform. Its products include the Probuphine implant for opioid use disorder treatment, among other programs for chronic pruritus, opioid relapse prevention, HIV prevention, and contraception.

Tags: HIV prevention, Pro Neura, chronic diseases, contraception, drug delivery, opioid use disorder, pharmaceutical, therapeutics

Symbol: TTNP

Recent Price: $3.40

Industry: Biotechnology

CEO: Jennifer Kiernan

Sector: Healthcare

Employees: 4

Address: 400 Oyster Point Boulevard, South San Francisco, CA 94080-1958

Phone: 650 244 4990

Leadership

  • Dato’ Seow Gim Shen, Chief Executive Officer and Chairman of the Board of Directors
  • Avraham Ben-Tzvi, Founder
  • Brynner Chiam, Vice President of Finance and Tax
  • Firdauz Edmin Bin Mokhtar, Chief Executive Officer
  • Francisco Osvaldo Flores García, Managing Partner

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc. logo
Market Cap: Low
Employees: Low

VGL101

Vigil Neuroscience, Inc. is a microglia-focused company developing disease-modifying therapeutics for neurodegenerative diseases. Their lead product candidate, VGL101, is a monoclonal antibody in Phase I trial for various neurodegenerative conditions.

Tags: TREM2, VGL101, biotechnology, microglia, neurodegenerative diseases, therapeutics

Symbol: VIGL

Recent Price: $1.53

Industry: Biotechnology

CEO: Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.

Sector: Healthcare

Employees: 64

Address: 1 Broadway, Cambridge, MA 02142

Phone: 857 254 4445

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31